| Mazzoni, Francesca |
| Active, not recruiting | 2 | 33 | Europe | Alectinib | Gruppo Oncologico Italiano di Ricerca Clinica | Non Small Cell Lung Cancer | 12/24 | 12/26 | | |
COMBI-TED, NCT04884282 / 2020-005170-10: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) |
|
|
| Recruiting | 2 | 105 | Europe | Tedopi, Nivolumab, Docetaxel | Fondazione Ricerca Traslazionale, Bristol Myer Squibb International Corporation, OSE Immunotherapeutics | Metastatic Non Small Cell Lung Cancer | 10/23 | 05/25 | | |
| Recruiting | 2 | 170 | Europe | Osimertinib, Tagrisso, Dacomitinib, Vizimpro | Fondazione Ricerca Traslazionale, Pfizer srl | NSCLC | 12/23 | 12/23 | | |
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). |
|
|
| Not yet recruiting | 2 | 142 | Europe | Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide | Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 08/28 | 06/29 | | |
